121 results about "Retinal Disorder" patented technology

According to the Mama and diffusion model-based OCTA fundus image generation system, method, medium and device provided by the invention, the unique Mama block is designed to effectively predict the accurate diffusion noise of the OCTA image from the OCT potential noise, the artifact of the generated image is reduced, and the contrast of the generated OCTA image is improved. Secondly, the proposed bidirectional Bow scanning scheme effectively alleviates the mechanism challenge of original Mama scanning, enhances the spatial continuity of the generated OCTA image, and improves the vascular extension of the generated image. Besides, the understanding ability of the OCT image is improved by combining a Mama block and a diffusion model through designed condition prompt, and the authenticity of the generated fundus OCTA image is further improved. According to experimental verification on two public data sets of OCTA500-3M and OCTA500-6M and one private data set, the SSIMs of 87.5% and 88.1% are achieved respectively, it is indicated that the fundus OCT image information can be fully utilized, the high-quality fundus OCTA image can be effectively generated, and new possibility is provided for low-cost screening of retinal diseases.

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

The present invention provides a novel therapeutic drug for treating a Prom1-associated retinal disease. Specifically, the present invention provides an optimized Prom1 gene expression cassette, an rAAV viral vector, and a gene therapy drug. The drug of the present invention can specifically express the PROM1 protein in the retinal photoreceptor layer, and is suitable for the clinical treatment of a retinal disease associated with Prom1 gene mutation.

The invention discloses a method for establishing an animal model for age-related retinopathy caused by lipid metabolism disorder, and the animal model is obtained by specifically knocking out Lss genes from mouse retinal pigment epithelium (RPE) cells by means of a CRISPR / Cas9 gene editing technology. The age-related retinopathy model mouse constructed by the invention shows a retinopathy phenotype with retinal lipid deposition and reduced visual function at the age of 5 months, and the retinopathy is further aggravated along with the increase of the age of the mouse and is similar to the phenotype of age-related retinopathy related to lipid metabolism disorder clinically; and an ideal and effective animal model is provided for researching age-related retinopathy.

The invention relates to a photoreceptor cell specific bidirectional promoter and application thereof. Specifically, the invention relates to a novel photoreceptor cell specific bidirectional promoter, an expression cassette containing the bidirectional promoter, a vector, a viral particle, a cell and a pharmaceutical composition, and application of the bidirectional promoter to treatment of eye diseases, such as retinal diseases.

The invention discloses application of a growth hormone receptor antagonist and a nucleic acid molecule in preparation of a medicine for preventing or treating retinal neovascularization diseases, and relates to the technical field of retinal neovascularization. The invention finds that the growth hormone receptor antagonist or the blocking reagent can effectively intervene the occurrence and development of the neovascular retina disease and improve the symptom of the disease. In addition, the transcription level of the encoding gene of the growth hormone receptor is reduced in a gene editing mode, and the pathological vascular change of the retinal neovascular disease can be effectively improved by knocking out the retina GHR, so that the pathological neovascular growth of the retina is reduced, and vascular exudation and inflammatory response are reduced. The invention provides a new direction for the treatment of retinal neovascular diseases, and provides a new choice for patients intolerant or unresponsive to anti-VEGF (Vascular Endothelial Growth Factor) treatment.

Disclosed herein are embodiments of a polymer-based implant and methods of making and using the same. The polymer-based implant comprises a polymer component and a therapeutic agent. In some embodiments, the polymer-based implant can be used to treat and / or prevent retinal diseases and / or retinopathies. The polymer-based implant exhibits physical properties that provide the ability to safely place the polymer-based implant in an ocular region without undesired diffusion and also to allow for controlled and timely release of the therapeutic agent to a desired region of the ocular region, such as the retina. In particular disclosed embodiments, the polymer-based implant can be used for safe and effective gene therapy.

Systems and relative method of monitoring the state of a subject's retinal disease employ remote based OCT imaging of a subject's retina. A method includes receiving optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina. The OCT image data of the retina is processed to determine a series of measured extent values. Each of the one or more measured extent values is indicative of a respective extent of the retinal disease.

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

The invention discloses a retinal vessel segmentation and lesion detection method based on incremental learning. The method comprises the specific steps that firstly, an original image of a data set STARE is acquired, and preprocessing such as segmentation and data enhancement is carried out on an original retina image; then, a VGAT-Net-IL network model is constructed, the network takes a coding-decoding symmetric structure as a trunk, a visual cortex mechanism is simulated through an adaptive receptive field module to dynamically adjust a receptive field, and local details and global features of the retinal vessels are cooperatively extracted; meanwhile, a dynamic bimodal attention module is innovatively integrated, variable convolution is introduced into the dynamic bimodal attention module to adaptively adjust a sampling position, a blood vessel region is precisely focused in combination with a space and channel attention mechanism, and after the dynamic bimodal attention module, a Bayesian semantic association module is introduced to generate features containing semantic association; in order to solve the problem that old knowledge is easy to forget when a model learns new lesion features, an incremental learning technology training model is introduced. According to the method, the retinal vessel segmentation precision and the lesion detection capability are improved, and a reliable image analysis basis is provided for retinal disease diagnosis.

The invention provides a novel therapeutic drug for treating Prom1 related retinal diseases. Specifically, the invention provides an optimized Prom1 gene expression cassette, an rAAV virus vector and a gene therapy drug. The medicine provided by the invention can specifically express the PROM1 protein in a retina photoreceptor layer, and is suitable for clinical application to treatment of Prom1 gene mutation related retinal diseases.

The invention provides a retina image registration method and system based on grid supervision and key point learning, and belongs to the technical field of medical image processing. The method comprises the following steps: acquiring an RGB fundus image pair; encoding the RGB eye fundus image pair through a shared feature extraction branch to obtain a down-sampling feature map; processing the down-sampling feature graph through a key point extraction branch and a descriptor decoder branch respectively, and extracting a key point probability graph and a feature descriptor; predicting the offset of the key points in the local window based on the paired feature descriptors through a key point offset prediction module; and carrying out position calibration on the key points in the key point probability graph based on the offset, and outputting a registered image. According to the method, self-supervised training is realized by using dense gridding marking points, and manual marking is not needed; through lightweight network design and a key point offset calibration mechanism, high registration precision is maintained while the parameter quantity is significantly reduced, and the method is suitable for clinical real-time deployment and retinal disease analysis.

Provided herein are method of treating retinal disease using a bisphosphonate acid sphingomyelinase (ASM) and farnesyl diphosphate synthase (FDPS) inhibitor, such as zoledronic acid, at low doses.

The present invention provides a C-terminal CDNF fragment sequence or a sequence which has at least 80% homology or sequence identity to said sequence. The C-terminal CDNF fragment protects ER stressed neurons, motoneurons and dopaminergic neurons and the fragment is capable of penetrating neuronal cell membrane as well as the blood-brain-barrier. The present invention further provides said fragment and pharmaceutical compositions comprising said fragment for use in treatments of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. The present invention is also providing a C-terminal MANF fragment sequence or a sequence which has at least 80% homology or sequence identity to the said sequence and pharmaceutical compositions comprising said MANF fragment for use in the treatment of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders.

The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Optical coherence tomography (OCT) data can be analyzed with neural networks trained on OCT data and known clinical outcomes to make more accurate predictions about the development and progression of retinal diseases, central nervous system disorders, and other conditions. The methods take 2D or 3D OCT data derived from different light source configurations and analyze it with neural networks that are trained on OCT images correlated with known clinical outcomes to identify intensity distributions or patterns indicative of different retina conditions. The methods have greater predictive power than traditional OCT analysis because the invention recognizes that subclinical physical changes affect how light interacts with the tissue matter of the retina, and these intensity changes in the image can be distinguishable by a neural network that has been trained on imaging data of retinas.

The present invention provides a multiomics approach, which integrate single-cell RNA-sequencing (scRNA-seq) and spatiotemporal transcriptomics (ST) offering potential for dissecting transcriptional networks and revealing cell-cell interactions involved in biomolecular pathomechanisms. The present invention also provides a multimodal approach combining high-throughput scRNA-seq and ST to elucidate XLRS-specific transcriptomic signatures in two XLRS-like models with retinal splitting phenotypes, including genetically engineered (Rs1emR209C) mice and patient-derived retinal organoids harboring the same patient-specific p.R209C mutation. Through multiomics transcriptomic analysis, the endoplasmic reticulum (ER) stress / eIF2 signaling, mTOR pathway, and the regulation of eIF4 and p70S6K pathways as chronically enriched and highly conserved disease pathways between two XLRS-like models are identified. Western blots and proteomics analysis validated the occurrence of unfolded protein responses, chronic eIF2α signaling activation, and chronic ER stress-induced apoptosis. Furthermore, therapeutic targeting of the chronic ER stress / eIF2α pathway activation synergistically enhanced the efficacy of AAV mediated RS1 gene delivery, ultimately improving bipolar cell integrity, postsynaptic transmission, disorganized retinal architecture and electrophysiological responses. Collectively, the complex transcriptomic signatures obtained from Rs1emR209C mice and patient-derived retinal organoids using the multiomics approach provide opportunities to unravel potential therapeutic targets for incurable retinal diseases, such as XLRS.

The invention relates to the technical field of biological medicine, in particular to application of aronia melanocarpa extract in prevention and / or treatment of retinal diseases. The invention discovers that the aronia melanocarpa extract effectively protects the functions of photoreceptor cells and bipolar cells by remarkably improving the expression of rhodopsin (RGO) and stem inhibition protein (SAG) genes in the retina and inhibiting the up-regulation of inflammatory factors TNF-alpha at the same time; in addition, cell apoptosis caused by light damage can be relieved by reducing TUNEL positive cells of the retinal outer nuclear layer (ONL), and therefore the structural integrity of the retina is maintained on the cellular level. Through the mechanisms, the aronia melanocarpa extract recovers normal electrophysiological reactions of photoreceptors and bipolar cells and protects the retina from further injury. The invention provides an effective strategy and theoretical basis for application of the aronia melanocarpa extract in prevention and treatment of retinal diseases caused by light damage.

The application provides an OCTA fundus image generation system, method, medium and device based on Mamba and diffusion model, the application effectively predicts the diffusion noise of the accurate OCTA image from the potential noise of the OCT by designing a unique Mamba block, reduces the artifacts of the generated image, and improves the contrast of the OCTA image generation. Secondly, the proposed bidirectional Bow scanning scheme effectively alleviates the mechanism challenge of the original Mamba scanning, enhances the spatial continuity of the generated OCTA image, and improves the blood vessel extension of the generated image. In addition, the designed conditional prompt improves the understanding of the OCT image in combination with the Mamba block and the diffusion model, and further improves the authenticity of the generated fundus OCTA image. The experimental verification on two public data sets of OCTA500-3M and OCTA500-6M and a private data set respectively reaches 87.5% and 88.1% of SSIM, indicating that the application can fully utilize the fundus OCT image information and effectively generate high-quality fundus OCTA images, providing a new possibility for low-cost screening of retinal diseases.

The application provides a FFA image generation system, method, medium and device based on a dual-domain constraint Mamba diffusion model, which integrates dual spatial and frequency domain constraints for cross-modal generation of FFA images from CFP images. Through a learnable wavelet feature extractor, the key frequency components of blood vessels are effectively extracted from the fundus CFP image, enhancing the structured guidance of the vascular edge representation in the generated FFA image. In the spatial domain, through a dual-pyramid feature extractor, the local details and global semantics of the fundus lesion area are effectively fused, improving the consistency of the lesion representation in the generated FFA image. The dual-domain conditional Mamba module serves as the denoising core, effectively coordinating spatial and frequency information to improve the clarity and accuracy of the image. The application is verified on the Hajeb, MPOS and clinical data sets, with PSNR reaching 30.11 and 29.40, effectively generating high-quality FFA images that retain vascular details, providing a new method for retinal disease screening.

The invention provides an application of teconazole (C26H31Cl2N5O3) or a pharmaceutical salt or a derivative thereof in a medicine for treating age-related retinal diseases, and relates to the technical field of biology. The application of the invention comprises the application of the teconazole or the pharmaceutical salt or the derivative thereof to the preparation of the medicine for treating, relieving and / or preventing the age-related retinal diseases. The invention proves that the Terconazole can relieve the senescence of retinal pigment epithelial cells and reduce the p53 protein content of the cells, provides a new candidate drug for the treatment of age-related retinal diseases, and has remarkable medical and clinical values.

A method and system for localizing a foveal center of a retina. An optical coherence tomography (OCT) volume for a retina of a subject is received. The OCT volume includes a plurality of OCT B-scans of the retina. A three-dimensional image input is generated for a model using the OCT volume. The model includes a three-dimensional convolutional neural network. The model is used to generate a foveal center position that includes three-dimensional coordinates for a foveal center of the retina based on the three-dimensional image input. The foveal center position may be used to generate an output that can be used in screening for retinal disease, diagnosing retinal disease, predicting treatment response, and / or managing retinal disease treatment.

Combination therapies including a Apurinic / Apyrimidinic Endonuclease / reduction-oxidation (redox) Factor-1 (APE1 / Ref-1) inhibitor specific to inhibit the redox function of APE1 / Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).

Systems and relative method of monitoring the state of a subject's retinal disease employ remote based OCT imaging of a subject's retina. A method includes receiving optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina. The OCT image data of the retina is processed to determine a series of measured extent values. Each of the one or more measured extent values is indicative of a respective extent of the retinal disease.

The RetinAI invention provides a novel integrated system designed for home-based early screening and detection of ocular tumors and retinal diseases, leveraging advanced artificial intelligence and optical imaging technology. The system comprises a wearable headset with precisely aligned imaging sensors and dual-mode illumination sources for capturing extraocular images to detect leukocoria and intraocular retinal images for direct visualization of tumors, eliminating the need for pharmacological pupil dilation. On-device deep learning models, including representative object detectors and convolutional neural networks, provide real-time diagnostic outputs. Clinical validations demonstrate RetinAI's capability to detect leukocoria as small as 1 mm in diameter and identify a broad spectrum of retinal diseases, confirming its significant potential to enhance ocular health screening, particularly in underserved and resource-limited settings. The cost-effective, user-friendly, and portable nature of the RetinAI system positions it as an essential tool for improving access to ophthalmic care globally.

Methods and systems for identifying a patient at increased risk for development of a retinal condition employ visual field tests. A method of identifying a patient at increased risk for development of a retinal condition includes monitoring the patient via one or more visual field tests. Each of the visual field tests includes displaying stimuli for viewing by an eye of the patient and receiving indications of locations of the stimuli as perceived by the patient. A visual field test score for each of the visual field tests is determined based on the stimuli and the indications of locations of the stimuli as perceived by the patient. In response to at least one of the visual field test scores exceeding a screening threshold, the patient is identified as being at increased risk for development of the retinal condition.

The invention discloses an OCTA image multi-target segmentation method based on an attention enhancement full-resolution network. According to the method, OCTA three-dimensional volume data is used as input, a height dimension is mapped to a channel dimension through Squeeze operation, and lossless dimension reduction is carried out; an attention-enhanced full-resolution module ARCB is constructed in combination with an improved Recurrent ConvNeXt module and an improved attention mechanism ES-CPCA, channel relation modeling and global context sensing are enhanced under the condition that downsampling is not carried out, and features of four types of structures including blood capillaries, arteries, veins and central non-vascular regions are considered. According to the method, the average segmentation precision and robustness of multi-target segmentation can be improved under the condition that only OCTA volume data is used, and a reliable basis can be provided for quantitative evaluation of retinal diseases.

The present disclosure provides for one or more embodiments for treating retinal degenerative disorders in a subject by administering to the subject an effective amount of allogeneic mesenchymal stem cells to the subject's suprachoroidal area. Allogeneic mesenchymal stem cells, when used in the disclosed treatment regimen, may exhibit anti-inflammatory, immunomodulatory, anti-fibrotic, pro-vascular, and / or pro-regenerative processes. Thus, allogeneic mesenchymal stem cells may be understood to have the potential to target and treat multiple pathological targets implicated in retinal degenerative disorders, including retinal disorders characterized by drusen accumulation, some of which have inherited forms.

The present application relates to a preparation method and application of photoreceptor precursor cells of human embryonic stem cell-derived retinal organoids, and belongs to the field of biotechnology and stem cell engineering. The present application constructs a lentiviral vector carrying an exogenous target gene and infects human embryonic stem cells to obtain a stable expression of engineered stem cell clone group by screening; the clone group is subjected to three-dimensional differentiation, and sequentially undergoes the formation of a blastoid, neural epithelial induction and retinal layering stage to obtain a retinal organoid; finally, the co-expression of photoreceptor precursor cell markers and exogenous genes in the organoid is identified. The present application realizes stable integration of genes at the source of stem cells, avoids the problem of low infection efficiency in the later stage, and provides a complete standardized scheme from gene modification, directional differentiation to function verification. The engineered photoreceptor precursor cells obtained by the method have important application value in the construction of retinal disease models, drug screening and cell therapy development.